Analysis of Antihypertensive Treatment Efficacy - Full Text View

Analysis of Antihypertensive Treatment Efficacy (ATACA)

This study is currently recruiting participants.

Verified by AstraZeneca, October 2008

First Received: October 6, 2008 No Changes Posted

Sponsored by:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00767247

Purpose

Analysis of antihypertensive treatment efficacy.

Condition
Arterial Hypertension

MedlinePlus related topics: Blood Pressure Medicines High Blood Pressure

U.S. FDA Resources

Study Type:	Observational
Study Design:	Case Control, Prospective
Official Title:	Analysis of Antihypertensive Treatment Efficacy

Further study details as provided by AstraZeneca:

Primary Outcome Measures:

Analysis of antihypertensive treatment efficacy. [ Time Frame: measurement BP: 3 visits for 3 month ] [ Designated as safety issue: No ]

Estimated Enrollment:	2000
Study Start Date:	May 2008
Estimated Study Completion Date:	February 2009

Groups/Cohorts
1 Male or female with arterial hypertension

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

outpatient clinics

Criteria

Inclusion Criteria:

arterial hypertension
intake of Atacand before study enrollment

Exclusion Criteria:

hypersensitivity to candesartan or any other ingredient of Atacand
liver function impairment and/or cholestasis
severe renal insufficiency (serum creatinine > 265 µmol/L)
woman of child-bearing potential and not using appropriate contraceptive measure

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00767247

Contacts

Contact: Russia Clinical Study Information

007-495-799-56-99

Irina.Obukhova@AstraZeneca.com

Locations

Russian Federation
Research Site	Recruiting
Arhangelsk, Russian Federation
Research Site	Recruiting
Bryansk, Russian Federation
Research Site	Recruiting
Domodedovo, Russian Federation
Research Site	Recruiting
Dzerzhinsk, Russian Federation
Research Site	Recruiting
Ekaterinburg, Russian Federation
Research Site	Recruiting
Essentuki, Russian Federation
Research Site	Recruiting
Volgograd, Russian Federation
Research Site	Recruiting
Irkutsk, Russian Federation
Research Site	Recruiting
Kazan, Russian Federation
Research Site	Recruiting
Samara, Russian Federation
Research Site	Recruiting
Severodvinsk, Russian Federation
Research Site	Recruiting
Vidnoe, Russian Federation
Research Site	Recruiting
Georgievsk, Russian Federation

Sponsors and Collaborators

AstraZeneca

Investigators

Principal Investigator:

Dmitry Zateyshchikov, MD, Prof

Federal State Institution of Russian President's General Management Department

More Information

No publications provided

Responsible Party:	Astra Zeneca, Russia ( Andrey Strugovshchikov, Medical Director )
Study ID Numbers:	NIS-CRU-ATA-2008/1
Study First Received:	October 6, 2008
Last Updated:	October 6, 2008
ClinicalTrials.gov Identifier:	NCT00767247 History of Changes
Health Authority:	Russia: Ethics Committee; Russia: Ministry of Health and Social Development of the Russian Federation

Keywords provided by AstraZeneca:

Arterial Hypertension

Study placed in the following topic categories:

Vascular Diseases
Cardiovascular Agents
Antihypertensive Agents
Hypertension

Additional relevant MeSH terms:

Therapeutic Uses
Vascular Diseases
Cardiovascular Diseases
Cardiovascular Agents

Antihypertensive Agents
Pharmacologic Actions
Hypertension

ClinicalTrials.gov processed this record on May 07, 2009